ArticleBMC musculoskeletal disorders2025
Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Efficacy of Calcitriol Combined with Denosumab versus Calcitriol Alone in Postmenopausal Osteoporosis: A Retrospective Cohort Study.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBisphosphonates and denosumab can increase bone mineral density (BMD) and are used to treat osteoporosis caused by aromatase inhibitors (AIs). However, few studies have been conducted on the effects of both on vertebral compression fractures (VCFs). This article aims to compare the effects of alendronate sodium and denosumab injection on the frequency of VCFs in postmenopausal women whose osteoporosis was brought on by AIs treatment for breast cancer.
methodsA retrospective cohort study was conducted from January 2020 to December 2024, enrolling 121eligible breast cancer patients with aromatase inhibitor-associated osteoporosis from the orthopedic outpatient department of Foshan Hospital of Traditional Chinese Medicine. Patients were divided into two treatment groups: the alendronate group received oral alendronate sodium tablets (70 mg once weekly), while the denosumab group received subcutaneous denosumab injections (60 mg every 6 months). Both groups were supplemented with calcitriol and calcium carbonate/vitamin D3 tablets as baseline therapy. The observation period was 12 months. The following parameters were compared between the two groups before and after treatment: BMD, 25-hydroxy Vitamin D3 (25-OH D3), β-C-terminal telopeptide of type I collagen (β-CTX) and Procollagen I N-Terminal Propeptide (PINP), Visual Analog Scale (VAS) scores and Incidence of VCFs. Statistical analysis was performed using SPSS 27.0.
resultsThe study included a total of 121 patients. Post-treatment analysis revealed a significantly higher overall response rate in the denosumab group(n = 57) (91.22%) compared to the alendronate group(n = 64) (82.81%; P < 0.05). Notably, the denosumab group demonstrated superior outcomes in the following two areas: (1) significantly greater improvement in BMD, (2) lower incidence of vertebral compression fractures (both P < 0.05). Both treatment groups showed statistically significant improvements in bone metabolism markers following treatment (P < 0.01).
conclusionBoth therapeutic regimens effectively improved BMD in the study population. However, comparative analysis revealed that denosumab injection (60 mg every 6 months) demonstrated significant advantages over weekly alendronate sodium (70 mg) in multiple clinical outcomes. Specifically, the denosumab group showed: (1) greater BMD improvement at all measured skeletal sites, and (2) a significantly lower incidence of VCFs (all P < 0.05) in postmenopausal women with aromatase inhibitor-associated osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.